摘要
背景与目的由于肾移植患者长期应用免疫抑制剂,与普通人群相比更易发生肿瘤。本研究中我们主要分析肾移植患者术后发生肿瘤的临床特点和预后,并评价根治性手术(radicalsurgery,RS)对其预后的影响。方法对本院1987年11月～2004年5月行肾移植手术的2160例患者进行回顾性分析,分析肾移植术后肿瘤的发生时间、肿瘤类型及生存时间等,总结肾移植术后肿瘤的发病特点。按是否行RS将肿瘤患者分为两组,对比研究RS对其预后的影响。结果2160例肾移植手术的患者中33例术后发生肿瘤,以消化系统肿瘤为主(33.3%)。10例行RS治疗(RS组)的患者中位生存时间为41.5个月;23例未行RS治疗(非RS组)者中位生存时间为6.0个月。两组20个月生存率分别为70.0%和13.0%。结论肾移植患者比普通人群更易发生肿瘤,肿瘤类型与普通人群所患不同,以肝癌、皮肤癌、淋巴瘤、甲状腺癌等为主。早期发现、早期治疗,尤其是病情允许行根治性手术者,近期疗效较好,远期效果有待进一步观察。
BACKGROUND & OBJECTIVE: Renal allograft recipients are more likely to develop neoplasm than general population because of long-term immunosuppressive treatment and concurrent infections. This study was designed to analyze the clinical features of neoplasm occurrence of renal allograft recipients, and the effect of radical surgery (RS) on their prognosis. METHODS: Records of 2 160 renal allograft recipients treated in our center from Oct. 1987 to Apr. 2003 were retrospectively studied. The time to neoplasm development, pathologic type of tumor, patients' survival time were analyzed to explore the clinical features of neoplasm developing after kidney transplantation. Recipients developed neoplasms were divided into RS group and non-RS group according to their treatment pattern. The effect of RS on patients' survival was estimated. RESULTS: A total of 33 patients developed neoplasms after transplantation. Among them,11(33.3%) developed neoplasms in digestive system. The median survival time of RS group (10 patients) was 41.5 months, that of non-RS group (23 patients) was 6.0 months. The 20-month survival rate of RS group was 70.0%, while that of non-RS group was 13.0%. CONCLUSIONS: Renal allograft recipients are more likely to develop neoplasm than general population. Moreover, their main malignancies are liver cancer, skin cancer, lymphoma and thyroid carcinoma, which differ from those observed in general population. Early diagnosis and treatment, especially feasible RS, will improve short-term outcome, while long-term therapeutic effect needs to be further observed.
出处
《癌症》
SCIE
CAS
CSCD
北大核心
2005年第2期222-225,共4页
Chinese Journal of Cancer
